Text Size

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Saitama Medical University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Non-Profit Organaizaion "LINE"
Information provided by:
Saitama Medical University
ClinicalTrials.gov Identifier:
NCT00288717
First received: February 7, 2006
Last updated: January 9, 2007
Last verified: January 2007
History of Changes
  Purpose

To investigate the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral fat by the newly developed Tele-medicine system


Condition Intervention
Hypertension
 Drug: Candesartan
Drug: Telmisartan

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Saitama Medical University:

Primary Outcome Measures:
  • Home blood pressure in the early morning

Secondary Outcome Measures:
  • Home blood pressure at bedtime
  • M/E ratio
  • Casual blood pressure
  • Body fat percentage
  • Body weight
  • Height
  • BMI
  • Blood potassium
  • Total cholesterol
  • HDL cholesterol
  • LDL cholesterol
  • Triglyceride
  • Blood glucose
  • IRI
  • HbAlc*
  • HOMA-IR
  • Urinary trace albumin
  • Creatinine

Estimated Enrollment: 300
Study Start Date: February 2006
Estimated Study Completion Date: September 2007
Detailed Description:

A randomized, comparative study of the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid metabolism in the hypertensive patients with the accumulation of visceral fat by the central registration system

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Circumference at waist: male ≧85 cm, female ≧90 cm
  • Hypertensive patient with untreated hypertension, and casual blood pressure of systole ≧140 mmHg, or diastole ≧90 mmHg
  • Hypertensive patient with hypertension under treatment, and casual blood pressure of systole ≧130 mmHg, or diastole ≧85 mmHg

Exclusion Criteria:

  • Significant hypertensive patient with diastolic blood pressure ≧120 mmHg
  • Malignant hypertensive patient
  • Patient with a contraindication to the study drugs (hypersensitivity, significant hepatic diseases, pregnant woman)
  • Patient with urinary protein (qualitative) ＋～＋＋
  • Patient with familial hyperlipidemia
  • Other patients judged as ineligible for the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00288717

Contacts
Contact: Hidetomo Nakamoto, MD +81-0492-76-1258 nakamo_h@saitama-med.ac.jp

Locations
Japan
Saitama Medical School Department of Renal Medicine Recruiting
Saitama City, Saitama, Japan, 350-0495
Contact: Hidetomo Nakamoto, MD     +81-492-76-1258     nakamo_h@saitama-med.ac.jp    
Principal Investigator: Hidetomo Nakamoto, MD            
Sponsors and Collaborators
Saitama Medical University
Non-Profit Organaizaion "LINE"
Investigators
Principal Investigator: Hidetomo Nakamoto, MD Saitama Medical School Department of Renal Medicine
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00288717     History of Changes
Other Study ID Numbers: FUJIYAMA-Study, UMIN-CTR-C000000324
Study First Received: February 7, 2006
Last Updated: January 9, 2007
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan
Candesartan cilexetil
Telmisartan
Antihypertensive Agents
Cardiovascular Agents
 Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 16, 2013